Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer.

BAT responders are distinct from non-responders in several ways however each of these distinctions are imperfect. Patterns of metastatic disease, prior therapies, duration of prior therapies, and genomics each contribute to an understanding of patients that will or will not respond. Additional studies are needed to refine the parameters that clinicians can utilize prior to choosing among the numerous treatment alternatives available for CRPC patients. This article is protected by copyright. All rights reserved.